Jason A. Dubovsky, Ph.D.
Affiliations: | 2011 | Biology (Cell Biology, Microbiology, Molecular Biology) | University of South Florida, Tampa, FL, United States |
Area:
Cell Biology, Immunology, Molecular BiologyGoogle:
"Jason Dubovsky"Parents
Sign in to add mentor| Javier A. Pinilla-Ibarz | grad student | 2011 | University of South Florida | |
| (Epigenetic Modifiers to Augment the Immunogenicity of Chronic Lymphocytic Leukemia.) | ||||
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Reiss DJ, Do T, Kuo D, et al. (2019) Multiplexed Immunofluorescence (IF) Analysis and Gene Expression Profiling of Biopsies from Patients with Relapsed/Refractory (R/R) Diffuse Large B Cell Lymphoma (DLBCL) Treated with Lisocabtagene Maraleucel (liso-cel) in Transcend NHL 001 Reveal Patterns of Immune Infiltration Associated with Durable Response Blood. 134: 202-202 |
| Kumar A, Vardhana S, Moskowitz AJ, et al. (2018) Pilot trial of ibrutinib in patients with relapsed or refractory T-cell lymphoma. Blood Advances. 2: 871-876 |
| Siddiqi T, Soumerai JD, Wierda WG, et al. (2018) Rapid MRD-Negative Responses in Patients with Relapsed/Refractory CLL Treated with Liso-Cel, a CD19-Directed CAR T-Cell Product: Preliminary Results from Transcend CLL 004, a Phase 1/2 Study Including Patients with High-Risk Disease Previously Treated with Ibrutinib Blood. 132: 300-300 |
| Cutler C, Jaglowski S, Arora M, et al. (2018) Ibrutinib for Chronic Graft-Versus-Host Disease: A Safety and Pharmacokinetic Analysis in Patients Treated with Concomitant Antifungal CYP3A Inhibitors or Immunosuppressants Biology of Blood and Marrow Transplantation. 24: S186-S187 |
| Sahaf B, Tebaykin D, Hopper M, et al. (2018) Ibrutinib-Mediated Inhibition of cGVHD Pathogenic Pre-Germinal Center B-Cells and Follicular Helper Cells While Preserving Immune Memory and Th1 T-Cells Biology of Blood and Marrow Transplantation. 24: S20-S21 |
| Miklos D, Cutler CS, Arora M, et al. (2017) Ibrutinib for chronic graft-versus-host disease after failure of prior therapy. Blood |
| Miklos DB, Jagasia MH, Greinix H, et al. (2017) A randomized, double-blind phase III study of ibrutinib versus placebo in combination with corticosteroids in patients with new onset chronic graft versus host disease. Journal of Clinical Oncology. 35: TPS7072-TPS7072 |
| Solman I, You H, Taylor M, et al. (2017) Ibrutinib vs chlorambucil: Immunophenotypic and quantitative impacts on circulating immune cells in chronic lymphocytic leukemia (CLL). Journal of Clinical Oncology. 35: 7524-7524 |
| Sahaf B, Tebaykin D, Hopper M, et al. (2017) Ibrutinib Inhibits cGVHD Pathogenic Pre-Germinal Center B-Cells and Follicular Helper Cells While Preserving Immune Memory and Th1 T-Cells Blood. 130: 4481-4481 |
| Natarajan G, Terrazas C, Oghumu S, et al. (2016) Ibrutinib enhances IL-17 response by modulating the function of bone marrow derived dendritic cells. Oncoimmunology. 5: e1057385 |